首頁 > 市場調查報告書 > 消費品

健康美容化妝品

市場調查報告書

商品編碼

1588567

全球長壽治療市場 - 2024-2031

Global Longevity Therapeutics Market - 2024-2031

出版日期: 2024年11月08日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

2023年，全球長壽治療市場規模達316.7億美元，預計2031年將達到520.3億美元，2024-2031年預測期間複合年成長率為6.4%。

長壽療法，也稱為長壽醫學或抗衰老醫學，是一個快速發展的領域，專注於幫助人們活得更長，過上更健康的生活。它採用多方面的方法，整合多種策略來解決老化的基本過程。

長壽治療方法包括標靶藥物治療、基因為基礎的干涉措施、再生醫學技術、營養補充劑和生活方式改變，所有這些都旨在減輕衰老的不利影響並促進健康長壽。該市場包括各種治療類別，包括藥物治療、基因療法、細胞療法和生活方式改變，所有這些都旨在解決衰老過程的不同方面。

市場動態：

司機

慢性病盛行率上升和人口老化

全球長壽治療市場的需求是由多種因素所驅動的。與老化相關的慢性疾病（包括心血管疾病、神經退化性疾病、癌症和代謝紊亂）的盛行率不斷增加，是推動長壽治療市場成長的主要因素。隨著全球人口持續老化，這些與年齡相關的疾病的發生率增加。

根據世界衛生組織 2022 年 10 月的資料，65 歲及以上人口的增加預計到2050 年將加倍，達到約15 億，人口老齡化和與年齡相關的疾病數量的增加將推動對醫療設備的需求。老年人口對預防性醫療保健重要性的認知不斷增強，這將推動對補充劑、藥物和生活方式改變的需求，以延長壽命和預防與年齡相關的疾病。

此外，行業研究活動的主要參與者和個人意識的提高正在推動長壽治療市場的成長。例如，2024 年2 月，西北大學范伯格醫學院的波托茨納克長壽研究所啟動了人類長壽實驗室，這是一項重要的縱向和橫斷面研究，旨在研究實際年齡（一個人的實際壽命）之間的聯繫）和生物年齡。這項研究旨在了解這兩種形式的老化在不同器官系統中如何相互關聯，並旨在驗證可能減緩或逆轉老化過程的干涉措施。

此外，在 2024 年 9 月的長壽科技新聞中，組合生物製劑正在成為一種有前途的長壽治療策略，特別是在與年齡相關的疾病方面。這種方法涉及使用多種生物製劑同時針對不同的途徑，有可能提高治療效果並解決老化的複雜本質。

同樣，2024 年 2 月，ADvantage Therapeutics 宣布任命 Makoto Kuro-o 教授為其科學顧問委員會成員，表彰他對衰老研究的先進貢獻，特別是發現與衰老和健康相關的 Klotho 基因。這項策略補充旨在加強公司對開發神經退化性疾病療法的關注。

限制

監管挑戰、倫理考量和有限的臨床證據等因素預計將阻礙市場的發展。

The longevity therapeutics approach encompasses targeted drug therapies, gene-based interventions, regenerative medicine techniques, nutritional supplements, and lifestyle modifications, all of which are aimed at mitigating the detrimental effects of aging and promoting healthy longevity. The market includes various therapeutic categories, including pharmacological treatments, gene therapies, cell therapies, and lifestyle changes, all aimed at addressing different facets of the aging process.

Market Dynamics: Drivers

Rising prevalence of chronic diseases and the aging population

The demand for the global longevity therapeutics market is driven by multiple factors. The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the longevity therapeutics market. As the global population continues to age, the occurrence of these age-related conditions rises.

As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the longevity therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.

Moreover, key players in the industry research activities and developing awareness among individuals, are driving longevity therapeutics market growth. For instance, in February 2024, The Potocsnak Longevity Institute at Northwestern University Feinberg School of Medicine launched the Human Longevity Laboratory, an important longitudinal and cross-sectional study aimed at examining the connection between chronological age (the actual number of years a person has lived) and biological age. This research seeks to understand how these two forms of aging relate to one another across various organ systems and aims to validate interventions that could potentially slow down or reverse the aging process.

Also, in Longevity Technology news in September 2024, combination biologics are emerging as a promising strategy for longevity therapy, particularly in age-related diseases. This approach involves using multiple biological agents that target different pathways simultaneously, potentially enhancing therapeutic efficacy and addressing the complex nature of aging.

Similarly, in February 2024, ADvantage Therapeutics announced the appointment of Professor Makoto Kuro-o to its Scientific Advisory Board, recognizing his advanced contributions to aging research, particularly for discovering the Klotho gene associated with longevity and health in aging. This strategic addition aims to enhance the company's focus on developing therapies for neurodegenerative diseases.

Restraints

Factors such as regulatory challenges, ethical considerations, and limited clinical evidence, are expected to hamper the market.

Segment Analysis

The global longevity therapeutics market is segmented based on product type, application, distribution channels, and region.

The dietary supplements segment accounted for approximately 76.3% of the global longevity therapeutics market share

The dietary supplements segment is expected to hold the largest market share over the forecast period. This segment includes a variety of formulations designed to promote health and longevity. This segment primarily features two categories: nutraceuticals and vitamins and minerals, both of which play crucial roles in enhancing overall health and preventing age-related diseases.

Nutraceuticals, natural compounds extracted from food sources, are crucial players in the longevity therapeutics market. These substances offer health advantages beyond basic nutrition, making them increasingly attractive to consumers who want to extend their health span and reduce the risk of age-related illnesses. Resveratrol, nicotinamide mononucleotide (NMN), and coenzyme Q10 (CoQ10) are key examples of these nutraceuticals.

Nicotinamide mononucleotide (NMN) plays a pivotal role in the longevity market as a supplement aimed at enhancing health and mitigating age-related decline. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial molecule involved in energy metabolism, DNA repair, and various cellular processes. As individuals age, NAD+ levels naturally decline, which can negatively affect cellular function and contribute to the onset of age-related conditions such as neurodegenerative diseases, metabolic disorders, and decreased energy levels.

Moreover, key players in the industry launching innovative products that would drive this segment's growth in the longevity therapeutics market. For instance, Decode Age introduced the MAG7, (Seven Complex Magnesium), and Coenzyme Q10 (Ubiquinol).

Decode Age, a pioneering health and wellness brand in India, has launched "Decode Blood Age," the country's first blood-based biological age test. This innovative approach aims to provide individuals with insights into their true health status by analyzing specific biomarkers derived from blood samples. Unlike chronological age, which simply reflects the number of years a person has lived, biological age reveals the rate at which an individual's body is aging on a cellular level.

Also, Zeropharm introduced clinically validated NMN 250 MG + Berberine Capsules, each containing 250 mg of high-purity NMN and powerful Berberine. These capsules are formulated to enhance NAD+ levels, boost energy, improve focus, support cellular health, promote heart health, and contribute to long-term longevity. For optimal results, take one capsule daily after your morning meal. Experience increased vitality and overall well-being.

Similarly, TeloX is an innovative, plant-derived supplement that combines a potent blend of therapeutic polyphenols naturally extracted from olive leaf, grapevine, and Superoxide Dismutase (SOD). These phytochemical compounds possess powerful antioxidant properties that neutralize harmful free radicals and provide essential nutrients to support mitochondrial function and promote cellular longevity.

Geographical Analysis

North America accounted for approximately 43.6% of the global longevity therapeutics market share

North America region is expected to hold the largest market share over the forecast period owing to the rising geriatric population and age-related diseases that would drive this market growth. Moreover, growing health consciousness, developments in biomedical research, and increased investment in longevity research and technological advancements would increase longevity therapeutics market growth in this region.

In addition, a major number of key players' presence, strategies such as partnerships & collaborations, and key developments would drive longevity therapeutics market growth. For instance, in April 2024, researchers at the Children's Hospital of Philadelphia (CHOP) and Stanford Medicine identified the FOXO1 protein as a critical factor in enhancing the longevity and effectiveness of CAR-T cells, which are engineered immune cells used in cancer treatment. This discovery is significant because the success of CAR-T cell therapy hinges on the ability of these cells to survive long enough in the body to effectively combat cancer.

Similarly, in California, in June 2024, Alamar Biosciences, a company focused on precision proteomics for early disease detection, announced the launch of the next phase of the Biomarkers of Aging Challenge Series in collaboration with the Biomarkers of Aging Consortium. This initiative aims to tackle one of the most pressing issues in the field of longevity, the need for reliable biomarkers that accurately reflect biological age.

Market Segmentation

By Product Type

Dietary Supplements
- NMN (Nicotinamide Mononucleotide)
- PQQ (Pyrroloquinoline quinone)
- Apigenin
- L-Tryptophan
- Others
Others

By Application

Senescence Inhibition
Cardiovascular Diseases
Cancer
Others

By Distribution Channel

Pharmacies
Online
Retail Stores

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major global players in the longevity therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. among others.

Key Developments

In September 2024, the Estate, introduced a luxury hospitality concept, has emerged from a collaboration between lifestyle company SBE, its visionary founder Sam Nazarian, and renowned entrepreneur Tony Robbins. This innovative venture seamlessly blends high-end accommodations with cutting-edge health and wellness services, catering to the increasing demand for longevity and disease prevention solutions.
In April 2024, the Longevity India Initiative, spearheaded by the Indian Institute of Science (IISc), embarks on a mission to propel research on aging and promote extended healthy lifespans in India. This far-reaching endeavor tackles the complex challenges of aging through a holistic, multidisciplinary approach that seamlessly blends expertise from the realms of biology, technology, and healthcare.

Why Purchase the Report?

To visualize the global longevity therapeutics market segmentation based on product type, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the longevity therapeutics market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.

The global longevity therapeutics market report would provide approximately 62 tables, 52 figures, and 183 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Chronic Diseases and Aging Population
- 4.1.2. Restraints
  - 4.1.2.1. Regulatory Challenges
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Dietary Supplements *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. NMN (Nicotinamide Mononucleotide)
- 6.2.4. PQQ (Pyrroloquinoline quinone)
- 6.2.5. Apigenin
- 6.2.6. L-Tryptophan
- 6.2.7. Others
6.3. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Senescence Inhibition*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiovascular Diseases
7.4. Cancer
7.5. Others

8. By Distribution Channels

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Pharmacies *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Online
8.4. Retail Stores

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Decode Age*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc.

LIST NOT EXHAUSTIVE